Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVoyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals Ltd

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.12 CAD 0.00(0%)
Last update at 2026-11-04T15:52:00Z
VOLUME
11024
Market Cap
17.86M

Momentum Score

…

Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The company has a collaboration with Bayer Aktiengesellschaft for the research and development of evaluating potential future production of iodine to be used in contrast media drugs. Voyageur Pharmaceuticals Ltd. was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. The company is headquartered in Calgary, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.12
Low
0.12
High
52 Week Price Range
0.10
Low
0.36
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Voyageur Pharmaceuticals Ltd, listed on the TSX Venture Exchange (VM.V), is a small-cap pharmaceutical company with limited public disclosure about its operations and product pipeline. Long-term growth could depend on successful clinical development, regulatory approvals and licensing or partnership deals, which may support commercialization and revenue.
Material risks include an unclear development-stage profile, low share liquidity, likely need for additional financing, and significant regulatory and execution risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.12
Dividend Yield
-
Revenue TTM
0.01M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.03
ROE
-415.01%
Net Debt
0.04M
ROCE
-273.32%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-11-30 2024-11-30 2023-11-30 2022-11-30 2021-11-30
Type yearly yearly yearly yearly yearly
Date 2025-11-30 2024-11-30 2023-11-30 2022-11-30 2021-11-30
Income before tax -3.53M -1.71M -1.40M -1.75M -2.05M
Net income -3.53M -1.71M -1.40M -1.75M -2.05M
Selling general administrative 1.98M 1.23M 0.38M 1.22M 1.55M
Selling and marketing expenses - - 0.28M 0.00M 0.00M
Gross profit 0.00M - -0.00M -0.00M -0.00M
Reconciled depreciation 0.00M 0.00M 0.00M 0.01M 0.00M
Ebit - - -1.35M -1.74M -2.05M
Ebitda - - -1.34M -1.74M -2.05M
Depreciation and amortization - - 0.00M 0.00M 0.00M
Operating income -3.53M -1.70M -1.35M -1.75M -2.05M
Other operating expenses - - 1.35M 1.75M 2.05M
Interest expense - 0.00M 0.00M 0.00M 0.00M
Net interest income - 0.00M -0.00M 0.00M -0.00M
Income tax expense - - 0.00M 0.00M -0.00M
Total revenue 0.01M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 3.54M 1.70M 1.34M 1.75M 2.05M
Cost of revenue 0.01M - 0.00M 0.00M 0.00M
Total other income expense net - -0.01M -0.05M -0.00M -0.00M
Net income from continuing ops -3.53M -1.71M -1.40M -1.75M -2.05M
Net income applicable to common shares - - - - -2.05M
Breakdown 2025-11-30 2024-11-30 2023-11-30 2022-11-30 2021-11-30
Type yearly yearly yearly yearly yearly
Date 2025-11-30 2024-11-30 2023-11-30 2022-11-30 2021-11-30
Total assets 3.11M 2.60M 2.16M 2.10M 2.57M
Other current assets - - 0.08M - -
Total liab 1.85M 2.15M 0.73M 0.63M 0.66M
Total stockholder equity 1.25M 0.45M 1.44M 1.46M 1.91M
Other current liab - 0.17M 0.67M - 0.05M
Common stock - - 8.69M - 6.27M
Capital stock 12.64M 9.14M 8.69M 7.55M 6.27M
Retained earnings -14.37M -10.84M -9.13M -7.73M -5.97M
Other liab - - - - 0.01M
Other assets - - 0.00M - 0.01M
Cash 0.27M 0.17M 0.00M 0.03M 0.81M
Total current liabilities 1.81M 2.09M 0.67M 0.59M 0.62M
Net debt - - 0.04M - -
Short long term debt total - - 0.04M - -
Other stockholder equity - - 1.86M - -
Property plant equipment - - - - 1.67M
Total current assets 0.60M 0.36M 0.09M 0.16M 0.89M
Net tangible assets - - - - 1.91M
Short term investments - - 0.00M - -
Net receivables 0.13M 0.05M 0.04M 0.02M 0.04M
Long term debt 0.04M 0.04M 0.04M 0.03M 0.03M
Inventory 0.05M 0.07M 0.01M 0.01M 0.01M
Accounts payable - - 0.00M 0.59M 0.55M
Accumulated other comprehensive income - - 0.01M - -
Non currrent assets other 0.01M 0.01M 2.06M 0.01M 0.01M
Non current assets total 2.51M 2.24M 2.08M 1.94M 1.68M
Capital lease obligations - - - 0.00M 0.02M
Breakdown 2025-11-30 2024-11-30 2023-11-30 2022-11-30 2021-11-30
Type yearly yearly yearly yearly yearly
Date 2025-11-30 2024-11-30 2023-11-30 2022-11-30 2021-11-30
Investments - -0.17M -0.17M -0.27M -0.43M
Change to liabilities - - - - -0.08M
Total cashflows from investing activities - - - - -0.43M
Net borrowings - - - - -0.02M
Total cash from financing activities 3.26M 0.63M 1.14M 1.21M 2.90M
Change to operating activities - - - - -0.26M
Net income -3.53M -1.71M -1.40M -1.75M -2.05M
Change in cash 0.10M 0.16M -0.03M -0.78M 0.81M
Begin period cash flow 0.17M 0.00M 0.03M 0.81M 0.00M
End period cash flow 0.27M 0.17M 0.00M 0.03M 0.81M
Total cash from operating activities -2.89M -0.30M -0.99M -1.72M -1.65M
Issuance of capital stock 0.91M 0.66M 1.20M 1.25M 2.31M
Depreciation 0.00M 0.00M 0.00M 0.01M 0.00M
Other cashflows from investing activities - - - - 0.00M
Change to inventory 0.02M -0.06M 0.00M -0.00M 0.00M
Change to account receivables - - -0.01M 0.02M -0.03M
Other cashflows from financing activities - - -0.06M 0.07M 0.61M
Change to netincome - - - - 0.74M
Capital expenditures 0.00M 0.00M 0.17M 0.28M 0.43M
Change in working capital -0.17M 0.93M 0.11M -0.24M -0.34M
Stock based compensation 0.81M 0.47M 0.23M 0.21M 0.74M
Other non cash items - - 0.31M 0.06M -0.00M
Free cash flow -2.89M -0.30M -1.17M -2.00M -2.09M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VM
Voyageur Pharmaceuticals Ltd		 -
-%		 0.12 - - 1528.34 15.69 1661.75 -5.74
RX
Biosyent Inc.		 0.25
1.48%		 17.10 19.10 15.85 3.96 4.11 3.31 11.03
DB
Decibel Cannabis Company Inc		 0.13
7.22%		 1.93 - 8.67 0.67 1.20 0.99 17.75
ZYUS
ZYUS Life Sciences Corporation		 0.03
9.38%		 0.35 - - 108.48 4.41 140.29 -4.26
LSL
LSL Pharma Group Inc.		 -
-%		 0.30 20.75 - 1.88 1.89 2.85 10.19

Profile*

Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The company has a collaboration with Bayer Aktiengesellschaft for the research and development of evaluating potential future production of iodine to be used in contrast media drugs. Voyageur Pharmaceuticals Ltd. was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. The company is headquartered in Calgary, Canada.

4103B Centre Street NW, Calgary, AB, Canada, T2E 2Y6

587 779 6166

https://voyageurpharmaceuticals.ca

Name Title Year Born
Mr. Brent Willis Bsc.Eng Pres, CEO & Director 1971
Mr. Bradley Craig Willis P.Eng. Founder, COO & Director 1971
Mr. Albert Deslauriers Chief Financial Officer NA
Mr. Brent Willis Bsc.Eng President, CEO & Director 1971
Mr. Ethan Mohan Sales Manager NA
Dr. Iryna Saranchova M.D., Ph.D. Chief Scientific Officer NA
Dr. Ibrahim Hashmi Vice President of Business Development NA
Mr. Ethan Mohan Executive Vice President NA
Mr. Kyle Peterson Head of Regulatory Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 29.99
+13.13%
AP-UN
CAD 4.19
+12.94%
ARTG
CAD 39.66
+12.93%
BZ
CAD 4.14
+10.99%
FFH
CAD 2759.48
+10.87%
DRUG
CAD 27.12
-26.86%
HUT
CAD 69.10
-22.27%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.85
-14.43%
MOON
CAD 4.09
-12.79%

Equity Sectors*

  • Basic Materials

    +3.69%

  • Communication Services

    +2.61%

  • Consumer Cyclical

    +2.96%

  • Consumer Defensive

    +1.11%

  • Energy

    -5.01%

  • Financial Services

    +2.20%

  • Healthcare

    -0.56%

  • Industrials

    -0.73%

  • Real Estate

    +1.90%

  • Technology

    +0.05%

  • Utilities

    +1.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…